search
Back to results

A Post-marketing Evaluation of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy

Primary Purpose

Cervical Radiculopathy

Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Qishe Pill
Sponsored by
Shanghai University of Traditional Chinese Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cervical Radiculopathy focused on measuring Neck pain, Cervical radiculopathy, Qishe Pill, Traditional Chinese Medicine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • clinical diagnosis of chronic neck pain since at least 3 months and complaints for a maximum duration of 5 years.
  • average pain intensity of the last 7 days more or equal to 25 points measured by a Neck Disability Index.
  • intellectual and physical ability to participate in the study. informed consent.
  • One positive result of Brachial Plexus Traction Test, Cervical compression test or Cervical distraction test

Exclusion Criteria:

  • cervical pain related to malignancy
  • cervical pain due to an accident
  • inflammatory joint disorders
  • previous spine surgery
  • protrusion/prolapse of a spinal disk, spondylolisthesis, with radicular symptomatology
  • actually doing or planning to do other regular physical exercise during the study with possible positive effects on neck pain - such as swimming, yoga, pilates, tai chi, etc.
  • use of pain drugs for other diseases (> 1x/week)
  • pregnancy
  • severe chronic or acute disease interfering with therapy attendance
  • alcohol or substance abuse
  • participation in another clinical trial in the last 6 months before study entry

Sites / Locations

  • Longhua Hospital, Shanghai University of TCMRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Qishe Pill

Arm Description

Outcomes

Primary Outcome Measures

pain severity(measured with a visual analogue scale, VAS)
Operationally, the VAS score display as a horizontal line, 100 mm in length, word descriptors anchored at each end. The patient marks on the line the point that they feel represents their perception of their current pain. The VAS score is then determined by measuring in millimetres from the left hand end of the line to the point that the patient marks.
pain severity(measured with a visual analogue scale, VAS)
Operationally, the VAS score display as a horizontal line, 100 mm in length, word descriptors anchored at each end. The patient marks on the line the point that they feel represents their perception of their current pain. The VAS score is then determined by measuring in millimetres from the left hand end of the line to the point that the patient marks.

Secondary Outcome Measures

SF-36
a composite of functional status
Neck Disability Index(NDI)
a composite of functional status
SF-36
a composite of functional status
Neck Disability Index(NDI)
a composite of functional status
Kidney function test
Liver function test
ECG
Occult Blood
Urine routine
Blood routine
Number of participants with Concomitant medication
Number of participants with Adverse Events

Full Information

First Posted
December 12, 2012
Last Updated
June 11, 2013
Sponsor
Shanghai University of Traditional Chinese Medicine
Collaborators
Huadong Hospital, Shanghai East Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai No.1 Hospital, Shanghai No.6 Hospital, Changhai Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01875562
Brief Title
A Post-marketing Evaluation of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy
Official Title
A Post-marketing Evaluation of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy
Study Type
Interventional

2. Study Status

Record Verification Date
June 2013
Overall Recruitment Status
Unknown status
Study Start Date
May 2012 (undefined)
Primary Completion Date
October 2013 (Anticipated)
Study Completion Date
November 2013 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shanghai University of Traditional Chinese Medicine
Collaborators
Huadong Hospital, Shanghai East Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai No.1 Hospital, Shanghai No.6 Hospital, Changhai Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Neck pain is a common symptom in most patients suffering from cervical radiculopathy. However, some conservative treatments are limited by their modest effectiveness. On the other hand, surgical intervention for cervical disc disorders is indicated when symptoms are refractory to conservative treatments and neurological symptoms are progressive. Many patients use complementary and alternative medicine, including Traditional Chinese Medicine, to address their symptoms. The purpose of the present study is to examine effectiveness and safety of Qishe Pill, a compound traditional Chinese herbal medicine, for neck pain in patients with cervical radiculopathy.
Detailed Description
Cervical radiculopathy is a distinct consideration in the evaluation of any patients who have neck pain and may be defined simply as an abnormality of a nerve root which originates in the cervical spine. The initial approach to the management of cervical spondylopathic radiculopathy is nearly the same as that of nonspecific neck or back pain that can be found in most patients. Conservative treatments include non-steroidal anti-inflammatory drugs (NSAIDs), narcotics, muscle relaxants, physical therapy and transcutaneous electrical nerve stimulation (TENS). The main objectives of conservative treatments are to relieve pain, improve function and improve health-related quality of life. However, these treatments for cervical radiculopathy are limited by their modest effectiveness. Surgical treatment for cervical disc disease is indicated when symptoms are refractory to conservative treatments and neurological symptoms are progressive. In terms of pharmacotherapy, there is generally no randomized, placebo-controlled trial available comparing standard nonsurgical treatment. Therefore, care plans should be designed principally based on accumulated experience, the services available locally, and the respective preferences of patients. Treatment plans are developed to alleviate pain, improve function, and prevent recurrences. As a complementary and alternative medicine (CAM), herbal medicines have the potential to avoid the adverse effects of medications and surgery.According to the basic theory of traditional Chinese medicine (TCM), the obstruction of Qi flow and blood circulation in the neck area caused by pathogenic factors, such as "Feng"(wind), "Han"(cold), "Shi"(dampness), invading the neck induces cervical degenerative disc diseases which are the cause of cervical radiculopathy. According to the four traditional methods of diagnosis -observation, listening, interrogation, and pulse-taking, TCM doctors can analyze the specific pathogenic factors which cause neck pain. Accordingly they can then prescribe herbal formulae based on the effect and the main indications according to the principles of Chinese medicine. Natural substances, including herbal medicines, have been used to promote healing and alleviate neck pain in western countries. Previous studies have demonstrated that some active substances in herbal medicine can promote Qi flow and blood circulation to alleviate pain.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Radiculopathy
Keywords
Neck pain, Cervical radiculopathy, Qishe Pill, Traditional Chinese Medicine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
2400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Qishe Pill
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Qishe Pill
Intervention Description
Pill, 3.75 g, twice per day, four weeks
Primary Outcome Measure Information:
Title
pain severity(measured with a visual analogue scale, VAS)
Description
Operationally, the VAS score display as a horizontal line, 100 mm in length, word descriptors anchored at each end. The patient marks on the line the point that they feel represents their perception of their current pain. The VAS score is then determined by measuring in millimetres from the left hand end of the line to the point that the patient marks.
Time Frame
changes from baseline at 2 weeks
Title
pain severity(measured with a visual analogue scale, VAS)
Description
Operationally, the VAS score display as a horizontal line, 100 mm in length, word descriptors anchored at each end. The patient marks on the line the point that they feel represents their perception of their current pain. The VAS score is then determined by measuring in millimetres from the left hand end of the line to the point that the patient marks.
Time Frame
changes from baseline at 4 weeks
Secondary Outcome Measure Information:
Title
SF-36
Description
a composite of functional status
Time Frame
changes from baseline at 2 weeks
Title
Neck Disability Index(NDI)
Description
a composite of functional status
Time Frame
changes from baseline at 2 weeks
Title
SF-36
Description
a composite of functional status
Time Frame
changes from baseline at 4 weeks
Title
Neck Disability Index(NDI)
Description
a composite of functional status
Time Frame
changes from baseline at 4 weeks
Title
Kidney function test
Time Frame
changes from baseline at 4 weeks
Title
Liver function test
Time Frame
changes from baseline at 4 weeks
Title
ECG
Time Frame
changes from baseline at 4 weeks
Title
Occult Blood
Time Frame
changes from baseline at 4 weeks
Title
Urine routine
Time Frame
changes from baseline at 4 weeks
Title
Blood routine
Time Frame
changes from baseline at 4 weeks
Title
Number of participants with Concomitant medication
Time Frame
4 weeks
Title
Number of participants with Adverse Events
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: clinical diagnosis of chronic neck pain since at least 3 months and complaints for a maximum duration of 5 years. average pain intensity of the last 7 days more or equal to 25 points measured by a Neck Disability Index. intellectual and physical ability to participate in the study. informed consent. One positive result of Brachial Plexus Traction Test, Cervical compression test or Cervical distraction test Exclusion Criteria: cervical pain related to malignancy cervical pain due to an accident inflammatory joint disorders previous spine surgery protrusion/prolapse of a spinal disk, spondylolisthesis, with radicular symptomatology actually doing or planning to do other regular physical exercise during the study with possible positive effects on neck pain - such as swimming, yoga, pilates, tai chi, etc. use of pain drugs for other diseases (> 1x/week) pregnancy severe chronic or acute disease interfering with therapy attendance alcohol or substance abuse participation in another clinical trial in the last 6 months before study entry
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xuejun Cui, Dr
Email
13917715524@139.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yongjun Wang, Dr
Organizational Affiliation
Longhua Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Longhua Hospital, Shanghai University of TCM
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200032
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xuejun Cui, Dr
Email
13917715524@139.com
First Name & Middle Initial & Last Name & Degree
Wen Mo, Dr
First Name & Middle Initial & Last Name & Degree
Yongjun Wang, Dr
First Name & Middle Initial & Last Name & Degree
Wen Mo, Dr

12. IPD Sharing Statement

Citations:
PubMed Identifier
33881718
Citation
Cui XJ, Sun YL, Zhang CQ, Wu T, Tan J, Zhu ZA, Chen YQ, Wang QG, Li M, Wang YJ. Post-Marketing Surveillance of Qishe Pill () Use for Management of Neck Pain in a Chinese Patient Cohort to Determine its Safety, Tolerability and Effectiveness. Chin J Integr Med. 2021 Jun;27(6):408-416. doi: 10.1007/s11655-021-2868-x. Epub 2021 Apr 21.
Results Reference
derived

Learn more about this trial

A Post-marketing Evaluation of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy

We'll reach out to this number within 24 hrs